171 related articles for article (PubMed ID: 34872775)
21. Effectiveness of first-line cetuximab in wild-type RAS metastatic colorectal cancer according to tumour BRAF mutation status from the EREBUS cohort.
Rouyer M; François E; Sa Cunha A; Monnereau A; Bignon E; Jové J; Lassalle R; Droz-Perroteau C; Moore N; Noize P; Fourrier-Réglat A; Smith D
Br J Clin Pharmacol; 2021 Mar; 87(3):1120-1128. PubMed ID: 32656857
[TBL] [Abstract][Full Text] [Related]
22. [Comparative study on prognosis of neoadjuvant chemotherapy followed by hepatic surgery versus upfront surgery in patients with synchronous colorectal liver metastasis].
Wang LJ; Wang HW; Jin KM; Liu W; Bao Q; Wang K; Xing BC
Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Mar; 24(3):248-255. PubMed ID: 34645169
[No Abstract] [Full Text] [Related]
23. Primary tumour location affects survival after resection of colorectal liver metastases: A two-institutional cohort study with international validation, systematic meta-analysis and a clinical risk score.
Gasser E; Braunwarth E; Riedmann M; Cardini B; Fadinger N; Presl J; Klieser E; Ellmerer P; Dupré A; Imai K; Malik H; Baba H; Ulmer H; Schneeberger S; Öfner D; Dinnewitzer A; Stättner S; Primavesi F
PLoS One; 2019; 14(5):e0217411. PubMed ID: 31150437
[TBL] [Abstract][Full Text] [Related]
24. Withholding the Introduction of Anti-Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild-Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study).
Palmieri LJ; Mineur L; Tougeron D; Rousseau B; Granger V; Gornet JM; Smith D; Lievre A; Galais MP; Doat S; Pernot S; Bignon-Bretagne AL; Metges JP; Baba-Hamed N; Michel P; Obled S; Vitellius C; Bouche O; Saban-Roche L; Buecher B; des Guetz G; Locher C; Trouilloud I; Goujon G; Dior M; Manfredi S; Soularue E; Phelip JM; Henriques J; Vernery D; Coriat R
Oncologist; 2020 Feb; 25(2):e266-e275. PubMed ID: 32043796
[TBL] [Abstract][Full Text] [Related]
25. Chemotherapy With or Without Anti-EGFR Agents in Left- and Right-Sided Metastatic Colorectal Cancer: An Updated Meta-Analysis.
Wang ZX; Wu HX; He MM; Wang YN; Luo HY; Ding PR; Xie D; Chen G; Li YH; Wang F; Xu RH
J Natl Compr Canc Netw; 2019 Jul; 17(7):805-811. PubMed ID: 31319395
[TBL] [Abstract][Full Text] [Related]
26. Maintenance treatment with capecitabine and bevacizumab versus observation in metastatic colorectal cancer: updated results and molecular subgroup analyses of the phase 3 CAIRO3 study.
Goey KKH; Elias SG; van Tinteren H; Laclé MM; Willems SM; Offerhaus GJA; de Leng WWJ; Strengman E; Ten Tije AJ; Creemers GM; van der Velden A; de Jongh FE; Erdkamp FLG; Tanis BC; Punt CJA; Koopman M
Ann Oncol; 2017 Sep; 28(9):2128-2134. PubMed ID: 28911067
[TBL] [Abstract][Full Text] [Related]
27. The effect of primary tumour resection on patients with synchronous metastatic colorectal cancer treated with cetuximab-containing regimens.
Sertesen E; Yekedüz E; Köksoy EB; Ürün Y; Erkek AB; Demirci S; Ünal AE; Utkan G
ANZ J Surg; 2023 Apr; 93(4):945-950. PubMed ID: 36259228
[TBL] [Abstract][Full Text] [Related]
28. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer.
Heinemann V; Rivera F; O'Neil BH; Stintzing S; Koukakis R; Terwey JH; Douillard JY
Eur J Cancer; 2016 Nov; 67():11-20. PubMed ID: 27592068
[TBL] [Abstract][Full Text] [Related]
29. Optimization of
Santos C; Azuara D; Garcia-Carbonero R; Alfonso PG; Carrato A; Elez ME; Gomez A; Losa F; Montagut C; Massuti B; Navarro V; Varela M; Lopez-Doriga A; Moreno V; Valladares M; Manzano JL; Vieitez JM; Aranda E; Sanjuan X; Tabernero J; Capella G; Salazar R
Mol Cancer Ther; 2017 Sep; 16(9):1999-2007. PubMed ID: 28626084
[TBL] [Abstract][Full Text] [Related]
30. Primary tumor sidedness is an independent prognostic marker for survival in metastatic colorectal cancer: Results from a large retrospective cohort with mutational analysis.
Kamran SC; Clark JW; Zheng H; Borger DR; Blaszkowsky LS; Allen JN; Kwak EL; Wo JY; Parikh AR; Nipp RD; Murphy JE; Goyal L; Zhu AX; Iafrate AJ; Corcoran RB; Ryan DP; Hong TS
Cancer Med; 2018 Jul; 7(7):2934-2942. PubMed ID: 29771009
[TBL] [Abstract][Full Text] [Related]
31. The impact of primary tumor localization on survival and treatment outcomes in patients with metastatic colorectal cancer-a multicenter study.
Sahin S; Karatas F
J BUON; 2019; 24(2):479-487. PubMed ID: 31127994
[TBL] [Abstract][Full Text] [Related]
32. Clinical Impact of PI3K/BRAF Mutations in RAS Wild Metastatic Colorectal Cancer: Meta-analysis Results.
Mohamed A; Twardy B; AbdAllah N; Akhras A; Ismail H; Zordok M; Schrapp K; Attumi T; Tesfaye A; El-Rayes B
J Gastrointest Cancer; 2019 Jun; 50(2):269-275. PubMed ID: 29388061
[TBL] [Abstract][Full Text] [Related]
33. Post-induction Strategies in Metastatic Colorectal Cancer Patients Treated With First-Line Anti-EGFR-Based Treatment: A Systematic Review and Meta-Analysis.
Parisi A; Ghidini M; Giampieri R; Tomasello G; Luciani A; Ferri C; Berardi R; Petrelli F
Clin Colorectal Cancer; 2022 Sep; 21(3):e162-e170. PubMed ID: 35184993
[TBL] [Abstract][Full Text] [Related]
34. Prognostic importance of tumor location and anti-EGFR therapy in patients with K-RAS wild type metastatic colorectal cancer.
Kucukoner M; Oztekin E; Akdeniz N; Morkuzu S; Yerlikaya H; Urakci Z; Kaplan MA; Isikdogan A
J BUON; 2019; 24(4):1501-1506. PubMed ID: 31646798
[TBL] [Abstract][Full Text] [Related]
35. Primary tumor location and survival among metastatic colorectal cancer patients treated with systemic chemotherapy and biologic therapies: Retrospective analysis.
Ramadan M; Alfayea T; Alsofyani A; Alyabsi M; Alhusseini N; Algarni AS
Cancer Treat Res Commun; 2022; 33():100632. PubMed ID: 36088745
[TBL] [Abstract][Full Text] [Related]
36. Prognostic significance of primary tumor localization in patients with metastatic colorectal cancer: Is it beneficial to select targeted treatment? Real-life experience from Turkey.
Cakan B; Acikgoz O; Bilici A; Demir T; Basak Oven B; Hamdard J; Olmuscelik O; Olmez OF; Seker M; Yildiz O
J BUON; 2021; 26(5):1908-1917. PubMed ID: 34761599
[TBL] [Abstract][Full Text] [Related]
37. Impact of primary tumour location and RAS/BRAF mutational status in metastatic colorectal cancer treated with first-line regimens containing oxaliplatin and bevacizumab: Prognostic factors from the AIO KRK0207 first-line and maintenance therapy trial.
Hegewisch-Becker S; Nöpel-Dünnebacke S; Hinke A; Graeven U; Reinacher-Schick A; Hertel J; Lerchenmüller CA; Killing B; Depenbusch R; Al-Batran SE; Lange T; Dietrich G; Tannapfel A; Arnold D
Eur J Cancer; 2018 Sep; 101():105-113. PubMed ID: 30036739
[TBL] [Abstract][Full Text] [Related]
38. Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies.
Boeckx N; Koukakis R; Op de Beeck K; Rolfo C; Van Camp G; Siena S; Tabernero J; Douillard JY; André T; Peeters M
Ann Oncol; 2017 Aug; 28(8):1862-1868. PubMed ID: 28449055
[TBL] [Abstract][Full Text] [Related]
39. Impact of primary tumour location on efficacy of bevacizumab plus chemotherapy in metastatic colorectal cancer.
Loupakis F; Hurwitz HI; Saltz L; Arnold D; Grothey A; Nguyen QL; Osborne S; Talbot J; Srock S; Lenz HJ
Br J Cancer; 2018 Dec; 119(12):1451-1455. PubMed ID: 30487637
[TBL] [Abstract][Full Text] [Related]
40. Factors Affecting the Efficacy of Regorafenib in Metastatic Colorectal Cancer: Is Tumour Sidedness Important?
Kazaz SN; Ozdover AC; Usta N; Yildirim A; Fidan E; Ozdemir F
J Coll Physicians Surg Pak; 2023 Jun; 33(6):659-665. PubMed ID: 37300262
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
